Proteomic Indicators of Health Predict Alzheimer's Disease Biomarker Levels and Dementia Risk

Abstract

Objective: Few studies have comprehensively examined how health and disease risk influence Alzheimer's disease (AD) biomarkers. The present study examined the association of 14 protein‐based health indicators with plasma and neuroimaging biomarkers of AD and neurodegeneration.Methods: In 706 cognitively normal adults, we examined whether 14 protein‐based health indices (i.e., SomaSignal Tests [SSTs]) were associated with concurrently measured plasma‐based biomarkers of AD pathology (Aβ42/40, pTau‐181), neuronal injury (neurofilament light chain [NfL]), and reactive astrogliosis (glial fibrillary acidic protein [GFAP]), brain volume, and cortical Aβ and tau. In a separate cohort (n = 11,285) we examined whether protein‐based health indicators associated with neurodegeneration also predict 25‐year dementia risk.Results: Greater protein‐based risk for cardiovascular disease, heart failure mortality, and kidney disease was associated with lower Aβ42/40 and higher pTau‐181, NfL, and GFAP levels, even in individuals without cardiovascular or kidney disease. Proteomic indicators of body fat percentage, lean body mass, and visceral fat were associated with pTau‐181, NfL, and GFAP, whereas resting energy rate was negatively associated with NfL and GFAP. Together, these health indicators predicted 12%, 31%, 50%, and 33% of plasma Aβ42/40, pTau‐181, NfL, and GFAP levels, respectively. Only protein‐based measures of cardiovascular risk were associated with reduced regional brain volumes; these measures predicted 25‐year dementia risk, even among those without clinically defined cardiovascular disease.Interpretation: Subclinical peripheral health may influence AD and neurodegenerative disease processes and relevant biomarker levels, particularly NfL. Cardiovascular health, even in the absence of clinically defined disease, plays a central role in brain aging and dementia.This article is protected by copyright. All rights reserved.

Alzheimer’s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline

“…Modifier-specific estimates were derived within the same model using linear combinations of relevant beta coefficients. Additional sensitivity analyses were performed without eGFR as a covariate even though kidney function has been previously shown to impact plasma biomarker concentration [ 46 – 48 ] likely due to poor renal clearance [ 49 ]. All continuous covariates were mean centered, sex was coded 0.5 for males and -0.5 for females.…”

SomaScan Bioinformatics: Normalization, Quality Control, and Assessment of Pre-Analytical Variation

“…These targets extensively cover major molecular functions including receptors, kinases, growth factors, and hormones, and span a diverse collection of secreted, intracellular, and extracellular proteins or domains. In recent years, SomaScan has increasingly been adopted as a powerful tool for biomarker discovery across a wide range of diseases and conditions, as well as to elucidate their biological underpinnings in proteomics and multi-omics studies 4–15 .…”